Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Modern Rheumatology|March 25, 2015
Modulation of immunological responses and amelioration of collagen-induced arthritis by the novel roxithromycin derivative 5-INoriko Otsuki, Satoshi Iwata, Taketo Yamada, et al.
Brain & Development|August 12, 2025
Survival motor neuron protein is the optimal biomarker for evaluating the risdiplam treatmentTamaki Kato, Noriko Otsuki, Mamoru Yokomura, et al.
Frontiers in Oncology|April 3, 2023
Replication stress increases mitochondrial metabolism and mitophagy in FANCD2 deficient fetal liver hematopoietic stem cellsMakiko Mochizuki-Kashio, Noriko Otsuki, Kota Fujiki, et al.
Immunology Letters|July 28, 2004
The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory rolePornpan Youngnak-Piboonratanakit, Fumihiko Tsushima, Noriko Otsuki, et al.
Orphanet Journal of Rare Diseases|February 28, 2025
Analysis of SMN protein in umbilical cord blood and postnatal peripheral blood of neonates with SMA: a rationale for prompt treatment initiation to prevent SMA developmentNoriko Otsuki, Tamaki Kato, Mamoru Yokomura, et al.
Biochemical and Biophysical Research Communications|August 2, 2003
Differential binding properties of B7-H1 and B7-DC to programmed death-1Pornpan Youngnak, Yuko Kozono, Haruo Kozono, et al.
European Journal of Immunology|September 30, 2003
Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responsesFumihiko Tsushima, Hideyuki Iwai, Noriko Otsuki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancerYuichiro Ohigashi, Masayuki Sho, Yukishige Yamada, et al.
Brain & Development|March 8, 2026
Outcomes of combination therapy with nusinersen, onasemnogene abeparvovec, and risdiplam over 3.5 years in a patient with prenatally diagnosed spinal muscular atrophy type 0: A case reportYukimune Okubo, Noriko Togashi, Yuko Morishita, et al.
Pageof 2